About the Company
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IDRA News
Should You Buy Idera Pharmaceuticals Inc (IDRA)?
That's why we believe it isn't a waste of time to check out hedge fund sentiment before you invest in a stock like Idera Pharmaceuticals Inc (NASDAQ:IDRA). Video: Click the image to watch our ...
Idera (IDRA) Stock Soars on GlaxoSmithKline Partnership
Separately, TheStreet Ratings team rates IDERA PHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation: We rate IDERA ...
Idera Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced that Robert Karr, M.D., President of Idera, will discuss the Company s Toll-Like Receptor - targeted drug discovery and development ...
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit ...
Idera Acquires Bootstrapped Data Visualisation Platform FusionCharts
As a part of the deal, FusionCharts will now be a part of Idera Inc’s developer tools business unit, which already includes software productivity brands like Embarcadero, Lansa, Sencha ...
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...
Ionis Pharmaceuticals Inc IONS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
ADIL Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead ...
PCSA Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are ...
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Q4 2023 Ionis Pharmaceuticals Inc Earnings Call
Brett P. Monia; Founder, CEO & Director; Ionis Pharmaceuticals, Inc. D. Wade Walke; SVP of IR; Ionis Pharmaceuticals, Inc. Elizabeth L. Hougen; Executive VP of ...
When Will Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Turn A Profit?
With the business potentially at an important milestone, we thought we'd take a closer look at Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) future prospects. Tarsus Pharmaceuticals, Inc., a ...
Loading the latest forecasts...